Magrolimab
- Generic Name
- Magrolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169232-81-7
- Unique Ingredient Identifier
- 90YIEHRFJ9
- Background
Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT06046482
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05929716
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05835011
- Locations
- 🇺🇸
BRCR Medical Center, Plantation, Florida, United States
🇺🇸Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Uwe Platzbecker
- Registration Number
- NCT05829434
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 44
- Registration Number
- NCT05823480
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Registration Number
- NCT05738161
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT05627466
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05367401
Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 77
- Registration Number
- NCT05330429
- Locations
- 🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸Virginia Cancer Specialists, PC, Arlington, Virginia, United States
🇺🇸Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 13
- Registration Number
- NCT05169944
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.